BRCA1 and breast cancer: As a first step to evaluate clinical relevance, we analyzed protein expression of topoisomerase I (TOP1) and P-cadherin (CDH3) in a large panel of breast cancer tissues from BRCA1/2 mutation carriers and women without a hereditary predisposition.